BG
CRBU icon

Bellevue Group’s Caribou Biosciences CRBU Stock Holding History

Bellevue Group’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-66,300
Closed -$699K – 172
2022
Q3 		$699K Sell
66,300
-4,000
-6% -$37.3K 0.01% 142
2022
Q2 		$382K Buy
+70,300
New +$537K 0.01% 148

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group's CRBU Position: Q4 2022 in Review

Bellevue Group sold out of Caribou Biosciences (CRBU) in Q4 2022, closing a stake of 66,300 shares — an estimated $699K sold.

Bellevue Group first reported a position in CRBU in Q2 2022 and held it in 2 quarters. The position peaked at $699K in Q3 2022. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2022.

  • Bellevue Group reported no remaining Caribou Biosciences position as of Q4 2022 after selling out during the quarter.
  • Bellevue Group sold 66,300 Caribou Biosciences shares in Q4 2022, an estimated $699K.
  • Bellevue Group first reported a position in Caribou Biosciences in Q2 2022 and held it in 2 quarters.
  • Bellevue Group's Caribou Biosciences position peaked at $699K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2022.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.